Clyde Biosciences is Drug Discovery in United Kingdom that focus on human-relevant cardiomyocyte business. Founded in 2012. They cover business area such as developer, cell analysis solution, risk, an early stage, disease, human-relevant cardiomyocyte functional datum, more accurate development, new medicine, cost, increase success, client, safe drug, market.
2012
( 12 years old in 2024 )
Human-relevant Cardiomyocyte
-
BioCity Scotland
Bo'Ness Road, Motherwell, Lanarkshire
Newhouse ML1 5UH
Scotland, United Kingdom
Private
developercell analysis solutionriskan early stagediseasehuman-relevant cardiomyocyte functional datummore accurate developmentnew medicinecostincrease successclientsafe drugmarket
* We use standard office opening hours in near Clyde Biosciences's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Clyde Biosciences is Drug Discovery business from United Kingdom that founded in 2012 (12 years old in 2024), Clyde Biosciences business is focusing on Human-relevant Cardiomyocyte.
Clyde Biosciences headquarter office and corporate office address is located in BioCity Scotland Bo'Ness Road, Motherwell, Lanarkshire Newhouse ML1 5UH Scotland, United Kingdom.
Clyde Biosciences was founded in United Kingdom.
In 2024, Clyde Biosciences is currently focus on human-relevant cardiomyocyte sector.
Above is snippet of Google Trends for "human-relevant cardiomyocyte" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Clyde Biosciences, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
